The aim of the present study was to evaluate the individual sensitivity of cancer patients to different antineoplastic drugs administered in standard protocols by assessing their acute cytogenetic effects on peripheral blood lymphocytes.
Methods and Study Design
In 12 patients undergoing cancer chemotherapy, acute cytogenetic effects on peripheral blood lymphocytes were evaluated by analysis of structural chromosome aberrations and micronuclei. All patients were given antineoplastic drugs, mainly as polychemotherapy. The frequencies of both cytogenetic biomarkers determined after the first chemotherapy cycle were compared with their pre-treatment (baseline) values.
Results
All chemotherapy protocols employed induced clear cytogenetic effects in both tests studied. The results obtained indicate interindividual variations between cytogenetic damage in peripheral blood lymphocytes among cancer patients. Statistically significant increases in the total number of structural chromosome aberrations and micronuclei in lymphocytes analyzed after chemotherapy compared to pre-therapy samples were observed in almost all patients studied. The highest level of chromosome damage as well as the highest incidence of micronuclei was observed following administration of the ACOP protocol (adriamycin, cyclophosphamide and vincristine). The proportions of signal-positive and signal-negative micronuclei were evaluated using DAPI staining, while silver staining revealed Ag-NOR+ and Ag-NOR− micronuclei. In some patients the incidence of signal-positive and Ag-NOR+ micronuclei after treatment was increased, indicating a more pronounced susceptibility of particular chromosomes to damage caused by antineoplastic drugs.
Conclusions
With regard to the results obtained we may conclude that both parameters used in the present study on peripheral lymphocytes are sensitive biomarkers and can be successfully employed for biomonitoring of acute cytogenetic effects induced by antineoplastic drugs in standard clinical protocols for cancer treatment.
International Agency for Research on Cancer (IARC): Some antineoplastic and immunosuppressive agents. IARC Monographs on the evaluation of carcinogenic risks to humans, 26: 411, 1981.
2.
International Agency for Research on Cancer (IARC): Some antiviral and antineoplastic drugs and other pharmaceutical agents. IARC Monographs on the evaluation of carcinogenic risks to humans, 76: 522, 2000.
3.
OthmanO.E.M.S.: Cytogenetic effect of anticancer drug epirubicin on Chinese hamster cell line in vitro. Mutat Res, 468: 109–115, 2000.
4.
HannsonJ.: Inherited defects in DNA repair and susceptibility to DNA-damaging agents. Toxicol Lett, 64/65: 141–148, 1992.
5.
SurallésJ., PuertoS., RamirezM.J., CreusA., MarcosR., MullendersL.H.F., NatarajanA.T.: Links between chromatin structure, DNA repair and chromosome fragility. Mutat Res, 404: 39–44, 1998.
6.
RibasM., MiróR., GelabertA., EgozcueJ.: Chromosome instability in lymphocytes from two patients affected by three sequential primary cancers: the role of fragile sites. Cancer Genet Cytogenet, 110: 133–135, 1999.
7.
AbdallahJ.M., LombardiD.P., KirschI.R.: Genetic instability in patients with Hodgkin's disease undergoing chemotherapy. J Clin Invest, 96: 2744–2747, 1995.
8.
ÇeçenerG., EgeliÜ., TasdelenI., TuncaB., DumanH., KizilA.: Common fragile site expression and genetic predisposition to breast cancer. Teratog Carcinog Mutagen, 18: 279–291, 1998.
9.
GebhartE., RomahnR., SchneiderA., HoffmannM., RauD., TittelbachH.: Cytogenetic studies in lymphocytes of patients with rectal cancer. Environ Health Perspect, 101: 169–175, 1993.
10.
WuX.F., SpitzM.R., DelclosG.L., ConnorT.H., ZhaoY., SicilianoM.J., HsuT.C.: Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev, 5: 527–532, 1996.
11.
DiamandidouE., BuzdarA.U., SmithT.L., FryeD., WitjaksonoM., HortobagyiG.N.: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas MD Anderson Cancer Center experience. J Clin Oncol, 14: 2722–2730, 1996.
12.
KelseyK.T., CagganaM., MauchP.M., ColemanC.N., ClarkJ.R., LiberH.L.: Mutagenesis after cancer therapy. Environ Health Perspect, 101: 177–184, 1993.
13.
PrattC.B., MeyerW.H., LuoX., CainA.M., KasteS.C., PappoA.S., RaoB.N., FlemingI.D., JenkinsJ.J.: Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer, 80: 960–965, 1997.
14.
SmithM.A., RubinsteinL., AndersonJ.R., ArthurD., CatalanoP.J., FreidlinB., HeynR., KhayatA., KrailoM., LandV.J., MiserJ., ShusterJ., VenaD.: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol, 17: 569–577, 1999.
15.
AronsonM.M., MillerR.C., HillR.B., NicholsW.W., MeadowsA.T.: Acute and long-term cytogenetic effects of treatment in childhood cancer. Sister-chromatid exchanges and chromosome aberrations. Mutat Res, 92: 291–307, 1982.
16.
CelottiL., BiasinR., FerraroP., FiorentinoM.: Effects of in vivo exposure to antineoplastic drugs on DNA repair and replication in human lymphocytes. Mutat Res, 245: 217–222, 1990.
17.
HancockS.L., TuckerM.A., HoppeR.T.: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst, 85: 25–31, 1993.
18.
PerryJ.R., BrownM.T., GockermanJ.P.: Acute leukemia following treatment of malignant glioma. J Neuro-Oncol, 40: 39–46, 1998.
19.
SartoF., TomaninR., GiacomelliL., CanovaA., RaimondiF., GhiottoC., FiorentinoM.V.: Evaluation of chromosomal aberrations in lymphocytes, oral mucosa and hair root cells of patients under antiblastic therapy. Mutat Res, 228: 157–169, 1990.
20.
TravisL.B., CurtisR.E., GlimeliusB., HolowatyE.J., Van LeeuwenF.E., LynchC.F., HagenbeekA., StovallM., BanksP.M., AdamiJ.: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst, 87: 524–530, 1995.
21.
KevekordesS., GebelT.W., HellwigM., DamesW., DunkelbergH.: Human effect monitoring in cases of occupational exposure to antineoplastic drugs: a method comparison. Occup Environ Med, 55: 145–149, 1998.
22.
CarbonellE., DemopoulosN.A., StefanouG., PsarakiK., ParryE.M., MarcosR.: Cytogenetic analysis in peripheral lymphocytes of cancer patients treated with cytostatic drugs: results from an EC Collaborative Study. Anti-Cancer Drug, 7: 514–519, 1996.
23.
HagmarL, BonassiS, StrömbergU, BroggerA, KnudsenLE, NorppaH, ReuterwallC, The European Study Group on Cytogenetic Biomarkers and Health: Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res, 58: 4117–4121, 1998.
24.
TuckerJ.D., PrestonR.J.: Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res, 365: 147–159, 1996.
25.
CollinsA., DusinskaM., FranklinM., SomorovskaM., PetrovskaH., DuthieS., FillionL., PanayiotidisM., RaslovaK., VaughanN.: Comet assay in human biomonitoring studies – reliability, validation, and applications. Environ Mol Mutagen, 30: 139–146, 1997.
26.
KopjarN., Garaj-VrhovacV.: Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical personnel handling antineoplastic drugs. Mutagenesis, 16: 71–78, 2001.
27.
OliveP.L.: The comet assay in clinical practice. Acta Oncol, 38: 839–844, 1999.
28.
VaghefH., NygrenP., EdlingC., BerghJ., HellmanB.: Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. Mutat Res, 395: 127–138, 1997.
29.
CarranoA.V., NatarajanA.T.: Considerations for population monitoring using cytogenetic techniques. Mutat Res, 204: 379–406, 1988.
30.
FenechM., MorleyA.A.: Measurement of micronuclei in lymphocytes. Mutat Res, 147: 29–36, 1985.
HowellW.M., BlackD.A.: Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experientia, 36: 1014–1015, 1980.
33.
CochónA.C., AldonattiC., San Martín De VialeL.C., Wainstok De CalmanoviciR.: Evaluation of the porphyrogenic risk of antineoplastics. J Appl Toxicol, 17: 171–177, 1997.
34.
CarranoA.V.: Chromosomal alterations as markers of exposure and effect. J Occup Med, 28: 1112–1116, 1986.
35.
FenechM.: Important variables that influence base-line micronucleus frequency in cytokinesis-blocked lymphocytes – a biomarker for DNA damage in human populations. Mutat Res, 404: 155–165, 1998.
36.
Jacobson-KramD., AlbertiniR.J., BrandaR.F., FaltaM.T., IypeP.T., KolodnerK., LiouS.H., McDiarmidM.A., MorrisM., NicklasJ.A., O'NeilJ.P., PoirierM.C., PutmanD., StricklandP.T., WilliamsJ.R., XiaoS.: Measurement of chromosomal aberrations, sister chromatid exchanges, hprt mutations, and DNA adducts in peripheral lymphocytes of human populations at increased risk for cancer. Environ Health Perspect, 101(suppl 3): 121–125, 1993.
37.
KirschvoldersM., ElhajoujiA., CundariE., VanhumelemP.: The in vitro micronucleus test – a multiendpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res, 392: 19–30, 1997.
38.
AnwarW.A.: Cytogenetic monitoring of human populations at risk in Egypt: role of cytogenetic data in cancer risk assessment. Environ Health Persp, 96: 91–95, 1991.
39.
NorppaH., LuomahaaraS., HeikanenH., RothS., SorsaM., RenziL., LindholmC.: Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogenes and clastogens. Environ Health Perspect, 101(suppl 3): 139–143, 1993.
40.
VenkatachalamP., SolomonF.D., MohankumarM.N., PrabhuB.K., GajendieanN., KathiresanA., JeevanramR.K.: Higher frequency of dicentrics and micronuclei in peripheral blood lymphocytes of cancer patients. Mutat Res, 425: 1–8, 1999.
41.
RothfussA., SchützP., BochumS., VolmT., EberhardtE., KreienbergR., VogelW., SpeitG.: Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA 1 mutation in breast cancer families. Cancer Res, 60: 390–394, 2000.
42.
PatelJ., RideoutD.: Synergism and antagonism in cancer chemotherapy. Cancer J, 5: 254–266, 1992.
43.
NovielloE., AluigiM.G., CimoliG., RoviniE., MazzoniA., ParodiS., De SessaF., RussoP.: Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks. Mutat Res, 311: 21–29, 1994.
44.
AndersonD., BishopJ.B., Colin GarnerR., Ostrosky-WegmanP., SelbyP.B.: Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res, 330: 115–181, 1995.
45.
González-CidM., CuelloM.T., LarripaI.: Comparison of the aneugenic effect of vinorelbine and vincristine in cultured human lymphocytes. Mutagenesis, 14: 63–66, 1999.
46.
Garaj-VrhovacV., KopjarN.: Micronuclei in cytokinesis-blocked lymphocytes as an index of occupational exposure to antineoplastic drugs. Radiol Oncol, 32: 385–392, 1998.
47.
TonfanelliS., StanyonR., AgostiniM., FranceschiM.G., PaoliG.: Variability of DA/DAPI and C-heterochromatic regions: a population study. Hum Biol, 65: 635–646, 1993.
48.
DerenziniM., SirriV., TrereD.: Nucleolar organizer regions in tumor cells. Cancer J, 7: 71–77, 1994.
49.
KlobusickáM., BabusikováO.: The relationship between argyrophilic proteins and some immunophenotypic markers in acute leukemia cells. Neoplasma, 44: 356–360, 1997.
50.
PedrazziniE., SlavutskyI.R.: Ag-NOR staining and satellite association in bone marrow cells from patients with mycosis fungoides. Hereditas, 123: 9–15, 1995.
51.
SurrallésJ., CatalanJ., CreusA., NorppaH., XamenaN., MarcosR.: Micronuclei induced by alachlor, mitomycin-C and vinblastine in human lymphocytes: presence of centromeres and kinetochores and influence of staining technique. Mutagenesis, 10: 417–423, 1995.
52.
WuX.F., ZhaoY., KempB.L., AmosC.I., SicilianoM.J., SpitzM.R.: Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer, 79: 490–493, 1998.
53.
KollmannsbergerC., HartmannJ.T., KanzL., BokemeyerC.: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Canc Res Clin Oncol, 124: 207–214, 1998.
54.
GreeneM.H., HarrisE.L., GershersonD.M.: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med, 105: 360–367, 1986.
55.
HaasJ.F., KittlemanB., MehnertW.H., StaneczekW., MöhnerM.: Risk of leukaemia in ovarian tumor and breast cancer patients following treatment by cyclophosphamide. Br J Cancer, 55: 213–218, 1987.
